HYPE!
Bulking season is finally upon us, and many will start planning their cycles and diets as they head into the long winter months. In light of recent industry rumors, it seems that Olympus UK is taking the season head on this year. Following the reports of a new estrogen blocker and updates to their PCT, sources have confirmed they’ll also be making changes to their popular on-cycle support product, Ar1macare Pro.
So far, we’ve heard that it will be upgraded to feature the same, yet unnamed aromatase inhibitor that Sup3r PCT and El1minate promise. This compound is billed as a more comprehensive approach to the on- and post-cycle formulas, boasting the ability to help regulate the conversion of testosterone to estrogen. During an anabolic cycle your body will be in testosterone overdrive, and adding on-cycle therapy that contains an aromatase inhibitor prevents extra estrogen from accumulating, thereby helping to minimize nasty side effects like water retention, excess fat storage, and even the dreaded gyno.
Research surround the compound suggests that it also aids in the reduction of bad cholesterol, in addition to possessing antioxidant and anti-inflammatory properties. These are crucial to improved recovery as you push your body to new limits during your intense training.

While we haven’t managed to snag a release date yet, sources say that the updated Ar1macare Pro should be released in time for those running anabolic cycles this season to take advantage of the improved formula. As always, subscribe to Strong Supplement Shop to be the first to get news on the release of Ar1macare Pro and other industry updates.
Sources
- Antioxidant and antimicrobial activities of fresh garlic and aged garlic by-products extracted with different solvents. 1
- Effects of S-1-propenylcysteine, a sulfur compound in aged garlic extract, on blood pressure and peripheral circulation in spontaneously hypertensive rats. 2
- Silybin Alleviates Hepatic Steatosis and Fibrosis in NASH Mice by Inhibiting Oxidative Stress and Involvement with the Nf-κB Pathway. 3